Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Howard

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201Edmund K Waller, Brent R Logan, Wayne A C Harris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomesNancy H Collins, Adrian P Gee, April G Durett, et al.
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
Bone Marrow Transplantation|December 19, 2023
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository studyPhilip L McCarthy, Kristopher M Attwood, Xiaojun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Blood|November 19, 2019
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trialJoseph Pidala, Mehdi Hamadani, Peter Dawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201Edmund K Waller, Brent R Logan, Wayne A C Harris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomesNancy H Collins, Adrian P Gee, April G Durett, et al.
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
Bone Marrow Transplantation|December 19, 2023
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository studyPhilip L McCarthy, Kristopher M Attwood, Xiaojun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Blood|November 19, 2019
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trialJoseph Pidala, Mehdi Hamadani, Peter Dawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S Hourigan, Laura W Dillon, Gege Gui, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Pageof 9